Parkinson's Disease Seven-Market Drug Forecast and Market Analysis

1.1 Summary of Changes
1.2 The PD market will grow to $7.0 billion
1.3 Novel symptomatic treatments will continue to shape the PD market
1.4 Opportunities and challenges for disease-modifying therapies entering the PD market
1.5 What do physicians think?

2.1 Catalyst
2.2 Related reports
2.3 Upcoming related reports

3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification or staging systems

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
4.4.1 Sources
4.4.2 Forecast assumptions and methods
4.4.3 Forecast assumptions and methods: diagnosed prevalent cases of PD
4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of PD by HY clinical staging
4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of PD by inheritance type
4.4.6 Forecast assumptions and methods: diagnosed prevalent cases of PD by motor complications
4.4.7 Forecast assumptions and methods: diagnosed prevalent cases of PD by neuropsychiatric complications
4.5 Epidemiological forecast for PD (2023-33)
4.5.1 Diagnosed prevalent cases of PD
4.5.2 Age-specific diagnosed prevalent cases of PD
4.5.3 Sex-specific diagnosed prevalent cases of PD
4.5.4 Diagnosed prevalent cases of PD by HY clinical staging
4.5.5 Diagnosed prevalent cases of PD by type
4.5.6 Diagnosed prevalent cases of PD by inheritance type
4.5.7 Diagnosed prevalent cases of PD by motor complications
4.5.8 Diagnosed prevalent cases of PD by neuropsychiatric complications
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 COVID-19 impact
4.6.3 Limitations of the analysis
4.6.4 Strengths of the analysis

5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management

6.1 Overview

7.1 Overview
7.2 Effective treatment of motor complications - dyskinesia, off episodes, gait, and balance problems
7.3 New therapies for non-motor complications - psychosis and dementia
7.4 Neuroprotective or disease-modifying agents
7.5 Formulations that reduce pill burden

8.1 Overview
8.1.1 Development of novel targets - targeting cell and gene therapies and a-synuclein
8.1.2 Innovative drug delivery systems
8.1.3 Secondary indications, post marketing requirements, and drug repurposing
8.2 Clinical trials design
8.2.1 Reliable biomarkers of disease progression
8.2.2 Genetic studies required to learn about genetic subtypes of PD

9.1 Overview
9.2 Promising drugs in clinical development

10.1 Overview
10.2 Competitive assessment
10.2.1 Levodopa therapies
10.2.2 Dopamine agonists/combinations
10.2.3 Antiparkinsonian agents targeting motor complications
10.2.4 Assets targeting PD dementia
10.2.5 Neuroprotective and disease-modifying agents

11.1 Overview
11.2 Deal-making trends

12.1 Global markets
12.1.1 Forecast
12.1.2 Drivers and barriers - global issues
12.2 US
12.2.1 Forecast
12.2.2 Key events
12.2.3 Drivers and barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key events
12.3.3 Drivers and barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key events
12.4.3 Drivers and barriers

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting methodology
13.4 Primary research - KOLs interviewed for this report
13.5 Primary research - prescriber survey
13.6 About the Authors
13.6.1 Analyst
13.6.2 Therapy Area Director
13.6.3 Epidemiologist
13.6.4 Managing Epidemiologists
13.6.5 Vice President of Disease Intelligence and Epidemiology
13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence

• About the Analyst
• Contact the Publisher

Table 1: Parkinson’s disease: key metrics in the 7MM
Table 2: Summary of changes to Parkinson’s Disease: Seven-Market Drug Forecast and Analysis report
Table 3: Modified HY scale of PD symptoms
Table 4: Movement Disorder Society-Sponsored Revision of the Unified PD Rating Scale (MDS-UPDRS), 2019
Table 5: Risk factors and comorbidities of PD
Table 6: Treatment guidelines for PD
Table 7: Top 10 deals by value, 2014-25
Table 8: PD market - global drivers and barriers, 2023-33
Table 9: Key events impacting sales for PD in the US, 2023-33
Table 10: PD market - drivers and barriers in the US, 2023-33
Table 11: Key events impacting sales for PD in the 5EU, 2023-33
Table 12: PD market - drivers and barriers in the US, 2023-33
Table 13: Key events impacting sales for PD in Japan, 2023 and 2033
Table 14: PD market - drivers and barriers in Japan, 2023-33
Table 15: High-prescribing physicians (non-KOLs) surveyed, by country

Figure 1: Global sales forecast by country for Parkinson’s disease in 2023 and 2033
Figure 2: Analysis of the company portfolio gap in PD during the forecast period
Figure 3: Competitive assessment of the late-stage pipeline agents that are investigated for disease-modifying/neuroprotective properties that the analyst expects to be licensed for the treatment of PD during the forecast period
Figure 4: 7MM, diagnosed prevalence of PD, both sexes, ages =18 years, %, 2023
Figure 5: 7MM, sources used and not used to forecast the diagnosed prevalent cases of PD
Figure 6: 7MM, sources used to forecast the diagnosed prevalent cases of PD segmented by HY clinical staging
Figure 7: 7MM, sources used to forecast the diagnosed prevalent cases of PD segmented by inheritance type
Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of PD segmented by motor complications
Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of PD segmented by neuropsychiatric complications
Figure 10: 7MM, diagnosed prevalent cases of PD, N, both sexes, ages =18 years, 2023
Figure 11: 7MM, age-specific diagnosed prevalent cases of PD, N, both sexes, 2023
Figure 12: 7MM, sex-specific diagnosed prevalent cases of PD, N, ages =18 years, 2023
Figure 13: 7MM, diagnosed prevalent cases of PD by HY clinical staging, both sexes, ages =18 years, N, 2023
Figure 14: 7MM, diagnosed prevalent cases of PD by type, both sexes, ages =18 years, N, 2023
Figure 15: 7MM, diagnosed prevalent cases of PD by inheritance type, both sexes, ages =18 years, N, 2023
Figure 16: 7MM, diagnosed prevalent cases of PD by motor complications, N, both sexes, ages =18 years, 2023
Figure 17: 7MM, diagnosed prevalent cases of PD by neuropsychiatric complications, N, both sexes, 2023
Figure 18: Treatment algorithm for PD patients: Treatment of Motor Complications
Figure 19: Unmet needs and opportunities in PD
Figure 20: Overview of PD pipeline in the 7MM
Figure 21: Key late-stage trials for the promising pipeline agents that the analyst expects to be licensed for PD in the 7MM during the forecast period
Figure 22: Competitive assessment of the pipeline levodopa therapies benchmarked against the SOC, Sinemet
Figure 23: Competitive assessment of the pipeline dopamine agonist drugs benchmarked against the SOC, Requip XL
Figure 24: Competitive assessment of the pipeline antiparkinsonian drugs benchmarked against the SOC, Gocovri
Figure 25: Competitive assessment of PD dementia agents benchmarked against the SOC, Exelon
Figure 26: Competitive assessment of the pipeline neuroprotective/DMT drugs benchmarked against the SOC, Azilect
Figure 27: Analysis of the company portfolio gap in PD during the forecast period
Figure 28: Global (7MM) sales forecast by country for PD in 2023 and 2033
Figure 29: Sales forecast by class for PD in the US in 2023 and 2033
Figure 30: Sales forecast by class for PD in the 5EU in 2023 and 2033
Figure 31: Sales forecast by class for PD in Japan in 2023 and 2033